Xiao Ni, MD, PhD
Department of Dermatology, Division of Internal Medicine
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Associate Member, The University of Texas, Graduate School of Biomedical Sciences, Houston, TX
Associate Professor, Dermatology - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Postgraduate Training
| 2000-2003 | Postdoctoral Fellow, Tumor immunology, Immunotherapy, Cutaneous T-cell Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 1988-1989 | Clinical Fellowship, Dermatopathology, Institution of Dermatology, The Chinese Academy of Medical Sciences, Nanjing |
| 1984-1988 | Resident physician, Dermatology, University of Nanjing - Affiliated Gulou Hospital, Nanjing |
| 1983-1984 | Clinical Intern, Internal Medicine, University of Nanjing - Affiliated Gulou Hospital, Nanjing |
Licenses & Certifications
| 1988 | Chinese Board of Dermatology |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2014
Adjunct Faculty, The University of Texas, Graduate School of Biomedical Sciences, Houston, TX, 2007 - 2013
Instructor, Dermatology, The University of Texas - MD Anderson Cancer Center, Houston, TX, 2004 - 2008
Attending Physician, Department of Dermatology, University of Nanjing - Affiliated Gulou Hospital, Nanjing, 1989 - 1994
Intramural Institutional Committee Activities
Member, Division of Internal Medicine Distinguished Paper Awards committee, The University of Texas MD Anderson Cancer Center, 2017 - Present
Member, Division of Internal Medicine Research Committee, The University of Texas MD Anderson Cancer Center, 2016 - Present
Extramural Institutional Committee Activities
Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2008 - 2010
Adjunct member, The University of Texas Graduate School of Biomedical Sciences - Advisory/Supervisory Committee, The University of Texas MD Anderson Cancer Center, 2007 - 2013
Member, Institutional Review Board, The University of Texas MD Anderson Cancer Center, 2003 - 2005
Honors & Awards
| 2021 | 2021 DoIM Excellent in Research, Division of Internal Medicine, MDACC |
| 2015 | Basic Research Distinguish Paper Award, Division of Internal Medicine |
| 2015 | Cyrus Scholar Award Finalist, Division of Internal Medicine Research Retreat |
| 2008 | Young Investigator Award, Cutaneous Lymphoma Foundation |
| 2007 | Cyrus Scholar Award Semi-Finalist, Division of Internal Medicine Research Retreat |
| 2005 | Research Grant Award, Ladies Leukemia League |
| 2003 | Research Grant Award, Dermatology Foundation |
| 2002 | Trainee Excellence Award, MD Anderson Alumni and Faculty Association |
| 1998 | Outstanding Young Investigator, The Institute of Dermatology, the Chinese Academy of Medicine and Sciences, China |
| 1996 | Graduate Student Excellence Award, The Chinese Academy of Medicine and Sciences, Peking Union Medial College, China |
| 1994 | Excellent Teacher, University of Nanjing - Affiliated Gulou Hospital, China |
| 1993 | Outstanding Employee, University of Nanjing - Affiliated Gulou Hospital, China |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Small-Molecule CCR4 Antagonists in Cutaneous T-cell Lymphoma. Invited. 2025 DoIM Research Grand Rounds. Houston, Texas, US.
- 2025. Effects of JAK/STAT inhibitors on cutaneous T-cell lymphoma cells. Poster. 2025 Internal Medicine Research Retreat & Poster Session. Houston, Texas, US.
- 2024. Characterization of tumor microenvironment in advanced skin lesions of cutaneous T-cell lymphoma by image mass cytometry. Poster. 2024 Internal Medicine Research Retreat & Poster Session. Houston, Texas, US.
- 2023. Effects of MALT1 Inhibitors on CTCL cells. Conference. 2023 DoIM Research Retreat. Houston, TX, US.
- 2022. Search for a cure for cutaneous T-cell lymphoma (CTCL). Conference. DoIM Research Grand Rounds. Houston, TX, US.
- 2021. Oncogenic JAK3 mRNA isoform in cutaneous T-cell lymphoma. Conference. 2021 DoIM Research Retreat. Houston, TX, US.
- 2020. Effects of CCR4 antagonists in cutaneous T-cell lymphoma cells. Conference. 2020 DoIM Research Retreat. Houston, TX, US.
- 2019. Detection of copy number variation and gene mutation in cell-free DNA of patients with cutaneous T-cell lymphoma. Conference. 2019 DoIM Research Retreat. Houston, TX, US.
- 2018. C1014T Single Nucleotide Polymorphism of CCR4 is frequent in Caucasian Patients with Cutaneous T-cell Lymphoma. Conference. 2018 DoIM Research Retreat. Houston, TX, US.
- 2017. Monitoring malignant T-cell clones by direct TCR expression assay in patients with leukemic cutaneous T-cell lymphoma over extracorporeal photopheresis. Conference. 2017 DoIM Research Retreat. Houston, TX, US.
- 2016. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. Conference. 2016 DoIM Research Retreat. Houston, TX, US.
- 2016. CD209+ monocyte-derived myeloid dendritic cells were increased in patients with leukemic cutaneous T-cell lymphoma after extracorporeal photopheresis. Conference. 2016 DoIM Research Retreat. Houston, TX, US.
- 2015. ONC201 induces apoptosis, inhibits proliferation, and affects cell cycle arrest in Cutaneous T-Cell Lymphoma Cells. Conference. 2015 DoIM Research Retreat. Houston, TX, US.
- 2015. The circulating cell-free DNA in patients with Cutaneous T cell lymphoma. Conference. 2015 DoIM Research Retreat. Houston, TX, US.
- 2014. Gene expression profiling of T-cell signaling in cutaneous T-cell lymphoma and the effect of extracorporeal photopheresis. Conference. 2014 DoIM Research Retreat. Houston, TX, US.
- 2012. Effect of extracorporeal photopheresis on Th1/Th2/Th17/Treg cytokines in cutaneous T-cell lymphoma patients. Conference. 2012 DoIM Research Retreat. Houston, TX, US.
- 2011. Extracorporeal photopheresis on dendritic cell populations in patients with Sézary syndrome and Graft-versus-Host disease and its correlation with the clinical response. Conference. 2011 DoIM Research Retreat. Houston, TX, US.
- 2010. Effect of extracorporeal photopheresis on dendritic cell populations in patients with Sézary syndrome and graft versus host disease. Conference. 2010 DoIM Research Retreat. Houston, TX, US.
- 2009. Foxp3 Expression is Induced in Peripheral Blood Mononuclear Cells from Patients with CTCL and GVHD after Extracorporeal Photopheresis. Conference. 2009 DoIM Research Retreat. Houston, TX, US.
- 2008. A novel approach to study tumor-specific CD8+ cytotoxic T lymphocyte in cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Conference. 2008 DoIM Research Retreat. Houston, TX, US.
- 2007. Immunologic mechanisms of extracorporeal photopheresis in cutaneous T-cell lymphomas versus chronic GvHD. Conference. 2007 Internal Medicine and Cancer Survivorship Grand Rounds. Houston, TX, US.
- 2007. Induction of Polyclonal T-cell Responses Directed Against Cutaneous T-cell Lymphomas by Autologous Dendritic Cells Transfected with Amplified Tumor RNA. Conference. 2007 DoIM research retreat. Houston, TX, US.
- 2004. Preclinical study on dendritic cell vaccine in Sezary Syndrome. Conference. Department of Melanoma Medical Oncology Seminar. Houston, TX, US.
Regional Presentations
- 1999. Psoriasis and keratinocyte apoptosis. Conference. Psoriasis and keratinocyte apoptosis. Nanjing, CN.
- 1998. Apoptosis in Pilomatricoma by in situ DNA Labeling Technique. Conference. Apoptosis in Pilomatricoma by in situ DNA Labeling Technique. Beijing, CN.
- 1997. The value of pathological examination in the diagnosis of atypical psoriasis. Conference. The value of pathological examination in the diagnosis of atypical psoriasis. Shanghai, CN.
National Presentations
- 2025. Effects of JAK/STAT inhibitors on cutaneous T-cell lymphoma cells. Poster. 2025 SID Annual Meeting. San Diego, California, US.
- 2024. Characterization of tumor microenvironment in advanced skin lesions of cutaneous T-cell lymphoma by image mass cytometry. Conference. The 2024 Societies for Investigative Dermatology Annual Meeting. Houston, Texas, US.
- 2022. Cancer associated fibroblasts in different T-stage lesions of cutaneous T-cell lymphoma. Conference. Cancer associated fibroblasts in different T-stage lesions of cutaneous T-cell lymphoma. Portland, OR, US.
- 2021. Oncogenic JAK3 mRNA isoform in cutaneous T-cell lymphoma. Conference. Oncogenic JAK3 mRNA isoform in cutaneous T-cell lymphoma. Virtual, US.
- 2020. Effects of CCR4 antagonists in cutaneous T-cell lymphoma cells. Conference. Effects of CCR4 antagonists in cutaneous T-cell lymphoma cells. Virtual, US.
- 2019. Detection of copy number variation and gene mutation in cell-free DNA of patients with cutaneous T-cell lymphoma. Conference. Detection of copy number variation and gene mutation in cell-free DNA of patients with cutaneous T-cell lymphoma. Houston, TX, US.
- 2018. ONC201 induces apoptosis in cutaneous T-cell lymphoma cells via activating integrated stress response and inactivating JAK/STAT and NFkB pathways. Conference. ONC201 induces apoptosis in cutaneous T-cell lymphoma cells via activating integrated stress response and inactivating JAK/STAT and NFkB pathways. La Jolla, CA, US.
- 2017. Monitoring malignant T-cell clones by direct TCR expression assay in patients with leukemic cutaneous T-cell lymphoma over extracorporeal photopheresis. Conference. Monitoring malignant T-cell clones by direct TCR expression assay in patients with leukemic cutaneous T-cell lymphoma over extracorporeal photopheresis. Portland, OR, US.
- 2016. CD209+ monocyte-derived myeloid dendritic cells were increased in patients with leukemic cutaneous T-cell lymphoma after extracorporeal photopheresis. Conference. CD209+ monocyte-derived myeloid dendritic cells were increased in patients with leukemic cutaneous T-cell lymphoma after extracorporeal photopheresis. New York, NY, US.
- 2016. CD209+ monocyte-derived myeloid dendritic cells were increased in patients with leukemic cutaneous T-cell lymphoma after extracorporeal photopheresis. Conference. CD209+ monocyte-derived myeloid dendritic cells were increased in patients with leukemic cutaneous T-cell lymphoma after extracorporeal photopheresis. Scottsdale, AZ, US.
- 2016. Genomic profiling of Sézary Syndrome reveals alterations in key T-cell signaling and differentiation genes. Conference. Genomic profiling of Sézary Syndrome reveals alterations in key T-cell signaling and differentiation genes. San Francisco, CA, US.
- 2016. The blood transcriptional profiling in patients with leukemic cutaneous T-cell lymphoma during extracorporeal photopheresis. Conference. 2016 T-Cell Lymphoma Forum. San Francisco, CA, US.
- 2015. The blood transcriptional profiling in patients with leukemic cutaneous T-cell lymphoma during extracorporeal photopheresis reveals integrin signal pathway associated with clinical response. Conference. The blood transcriptional profiling in patients with leukemic cutaneous T-cell lymphoma during extracorporeal photopheresis reveals integrin signal pathway associated with clinical response. Orlando, FL, US.
- 2015. ONC201 Induces Apoptosis in Cutaneous T-Cell Lymphoma Cells through a Mechanism that Involves the Integrated Stress Response and Inactivation of Jak/Stat Signaling. Conference. ONC201 Induces Apoptosis in Cutaneous T-Cell Lymphoma Cells through a Mechanism that Involves the Integrated Stress Response and Inactivation of Jak/Stat Signaling. Orlando, FL, US.
- 2015. Circulating cell-free DNA is increased in sera of Sézary syndrome patients. Conference. Circulating cell-free DNA is increased in sera of Sézary syndrome patients. Atlanta, GA, US.
- 2015. Circulating cell-free DNA is increased in sera of Sézary syndrome patients. Conference. Circulating cell-free DNA is increased in sera of Sézary syndrome patients. Atlanta, GA, US.
- 2015. HIGH SENSITIVITY OF CUTANEOUS T-CELL LYMPHOMA (CTCL) TO CABE, A COMPONENT OF PROPOLIS. Conference. HIGH SENSITIVITY OF CUTANEOUS T-CELL LYMPHOMA (CTCL) TO CABE, A COMPONENT OF PROPOLIS. Philadelphia, PA, US.
- 2014. Gene expression profiling of T-cell signaling in cutaneous T-cell lymphoma and the effect by extracorporeal photopheresis. Conference. Gene expression profiling of T-cell signaling in cutaneous T-cell lymphoma and the effect by extracorporeal photopheresis. Albuquerque, NM, US.
- 2013. Whole Exome Sequencing and Analysis of Mutations in Sézary Syndrome. Conference. The 55th annual meeting of American Society of Hematology. New Orleans, LA, US.
- 2012. Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4). Conference. The 54th annual meeting of American Society of Hematology. Atlanta, GA, US.
- 2012. Effect of extracorporeal photopheresis on Th1/Th2/Th17/Treg cytokines in cutaneous T-cell lymphoma patients. Conference. Cutaneous T-cell Lymphoma Symposium 2012. Raleigh, NC, US.
- 2011. Effects of Anti-CCR4 Antibody (KW-0761) on Regulatory T Cells and Natural Killer Cells in Patients with Cutaneous T-Cell Lymphoma. Conference. Effects of Anti-CCR4 Antibody (KW-0761) on Regulatory T Cells and Natural Killer Cells in Patients with Cutaneous T-Cell Lymphoma. San Diego, CA, US.
- 2008. Foxp3 Expression is Induced in Peripheral Blood Mononuclear Cells from Patients with CTCL and GVHD after Extracorporeal Photopheresis. Conference. Foxp3 Expression is Induced in Peripheral Blood Mononuclear Cells from Patients with CTCL and GVHD after Extracorporeal Photopheresis, CA, US.
- 2007. Induction of polyclonal T-cell responses against cutaneous T-cell lymphoma by autologous dendritic cells transfected with amplified tumor RNA. Conference. Induction of polyclonal T-cell responses against cutaneous T-cell lymphoma by autologous dendritic cells transfected with amplified tumor RNA. Los Angeles, CA, US.
- 2006. Anti-angiogenic effect of vorinostat (suberoylanilide hydroxamic acid, SAHA), a histone deacetylase inhibitor, in CTCL lesions. Conference. Mycosis Fungoides Foundation. Philadelphia, PA, US.
- 2006. Interleukin-23 is increased in mycosis fungoides lesions and decreased in Sézary Syndrome. Conference. Interleukin-23 is increased in mycosis fungoides lesions and decreased in Sézary Syndrome. Philadelphia, PA, US.
- 2005. UVB induced - apoptotic Sézary cells are superior to tumor cell lysates in priming of IFN-α -secreting cytotoxic T cells in vitro. Conference. UVB induced - apoptotic Sézary cells are superior to tumor cell lysates in priming of IFN-α -secreting cytotoxic T cells in vitro. St. Louis, MO, US.
- 2004. Apoptotic cells and tumor cell lysate pulsed CD14+monocyte-derived dendritic cells from cutaneous T-cell lymphoma mature and induce allogeneic T-cell proliferation in vitro. Conference. Apoptotic cells and tumor cell lysate pulsed CD14+monocyte-derived dendritic cells from cutaneous T-cell lymphoma mature and induce allogeneic T-cell proliferation in vitro. Providence, RI, US.
- 2002. Functional Fas ligand is expressed in human cutaneous T cell lymphoma cells and inhibited by Bexarotene. Conference. Functional Fas ligand is expressed in human cutaneous T cell lymphoma cells and inhibited by Bexarotene. Los Angeles, CA, US.
- 2001. Fas/Fas ligand-mediated elimination of cytotoxic CD8+ lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?. Conference. Fas/Fas ligand-mediated elimination of cytotoxic CD8+ lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?. Washington DC, US.
International Presentations
- 2023. Machine Learning in the Genomic-Clinical Classification of Cutaneous T-Cell Lymphoma. Conference. Machine Learning in the Genomic-Clinical Classification of Cutaneous T-Cell Lymphoma, SG.
- 2023. Effects of MALT1 Inhibitors on cutaneous T-cell lymphoma cells. Conference. Effects of MALT1 Inhibitors on cutaneous T-cell lymphoma cells. Tokyo, JP.
- 2022. Silencing JAK3-INSL3 inhibits cell proliferation and colony forming of cutaneous T-cell lymphoma cells. Conference. Silencing JAK3-INSL3 inhibits cell proliferation and colony forming of cutaneous T-cell lymphoma cells, US.
- 2021. Oncogenic JAK3 mRNA isoform in cutaneous T-cell lymphoma. Conference. Oncogenic JAK3 mRNA isoform in cutaneous T-cell lymphoma. Virtual, US.
- 2019. Detection of copy number variation and gene mutation in cell-free DNA of patients with cutaneous T-cell lymphoma. Conference. International Society for Cutaneous Lymphomas (ISCL) Cutaneous Lymphoma Symposium. Chicago, US.
- 2018. C1014T single nucleotide polymorphism of CCR4 is frequent in Caucasian patients with cutaneous T-cell lymphoma. Conference. International Investigative Dermatology (IID) 2018 Meeting. Orlando, US.
- 2014. Effects of anti-CCR4 antibody (KW-0761) on regulatory T cells and natural killer cells in CTCL patients. Conference. Nanjing, CN.
- 2013. Potential driver genes in the development and progression of cutaneous T-cell lymphoma. Conference. Potential driver genes in the development and progression of cutaneous T-cell lymphoma. Edinburgh.
- 2012. Effect of extracorporeal photopheresis on Th1/Th2/Th17/Treg cytokines in cutaneous T-cell lymphoma patients. Conference. Effect of extracorporeal photopheresis on Th1/Th2/Th17/Treg cytokines in cutaneous T-cell lymphoma patients. Raleigh, US.
- 2011. Effect of extracorporeal photopheresis on dendritic cell populations in patients with Sézary syndrome and Graft-versus-Host disease and its correlation with the clinical response. Conference. Cutaneous T-cell Lymphoma Symposium 2011. Phoenix, US.
- 2010. Preliminary results for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in PTCL and CTCL patients: Antigen expression may correspond to higher likelihood of clinical response. Conference. Preliminary results for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in PTCL and CTCL patients: Antigen expression may correspond to higher likelihood of clinical response. Chicago, US.
- 2010. The expression of CCR4 in PTCL/CTCL skin lesions and its correlation with the skin response to KW-0761. Conference. The expression of CCR4 in PTCL/CTCL skin lesions and its correlation with the skin response to KW-0761. Chicago, US.
- 2010. The expression of CCR4 in PTCL/CTCL skin lesions and its correlation with the skin response to KW-0761. Conference. The expression of CCR4 in PTCL/CTCL skin lesions and its correlation with the skin response to KW-0761. Chicago, US.
- 2010. Increased Twist expression in advanced stage of cutaneous T-cell lymphoma. Conference. Cutaneous T-cell Lymphoma Symposium 2010. Atlanta, US.
- 2009. Immunologic mechanisms of extracorporeal photopheresis in cutaneous T-cell lymphomas. Conference. Immunologic mechanisms of extracorporeal photopheresis in cutaneous T-cell lymphomas. Beijing, CN.
- 2009. Increased Syndecan-4 expression in malignant T -lymphocytes is associated with progression in Mycosis Fungoides. Conference. Increased Syndecan-4 expression in malignant T -lymphocytes is associated with progression in Mycosis Fungoides. Montreal, CA.
- 2009. Increased levels of CD4+25high regulatory T cells in patients with cutaneous T-cell lymphoma after extracorporeal photopheresis treatment. Conference. Increased levels of CD4+25high regulatory T cells in patients with cutaneous T-cell lymphoma after extracorporeal photopheresis treatment. Montreal, CA.
- 2008. A novel approach to study tumor-specific CD8+ cytotoxic T lymphocyte in cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Conference. A novel approach to study tumor-specific CD8+ cytotoxic T lymphocyte in cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. Kyoto, JP.
- 2003. Tazarotene induced gene-3 is suppressed in basal cell carcinomas and upregulated by tazarotene in vivo. Conference. Tazarotene induced gene-3 is suppressed in basal cell carcinomas and upregulated by tazarotene in vivo. Miami, US.
Formal Peers
- 2014. Effects of anti-CCR4 antibody (KW-0761) on regulatory T cells and natural killer cells in CTCL patients. Invited. Nanjing, Jiangsu, CN.
- 2009. My physician-scientist journey. Invited. Nanjing, CN.
- 2009. Mechanisms of extracorporeal photopheresis in the treatment of Cutaneous T-cell lymphoma. Invited. Nanjing, CN.
- 2009. Extracorporeal photopheresis and its clinical implications. Invited. Beijing, CN.
- 2006. Preclinical study on dendritic cell vaccine in Sezary Syndrome. Invited. Cambridge, MA, US.
- 2004. Preclinical study on dendritic cell vaccine in Sezary Syndrome. Houston, Texas, US.
Grant & Contract Support
| Date: | 2023 - Present |
| Title: | Topical Janus kinas inhibition in early-stage mycosis fungoides |
| Funding Source: | Institutional Research Grant (IRG) |
| Role: | Co-I |
| ID: | 2023-00062821 |
| Date: | 2023 - 2026 |
| Title: | Dissecting immune determinants in lesional skins of patients with cutaneous T-cell lymphoma undergoing Mogamulizumab therapy |
| Funding Source: | Institutional Research Grant (IRG) |
| Role: | PI |
| ID: | 2023-00062067 |
| Date: | 2022 - 2023 |
| Title: | CCR4 antagonists in cutaneous T-cell lymphoma (CTCL) (AWD00006641) |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| ID: | FP/RCTS ID: FP00009966_Res1 |
| Date: | 2022 - Present |
| Title: | Investigation of Pathogenesis and Therapeutic Drugs in Cutaneous T-cell Lymphoma |
| Funding Source: | Fred Pearce Fund for CTCL Research |
| Role: | PI |
| Date: | 2020 - Present |
| Title: | Evaluation of CCR4-351 on cutaneous T-cell lymphoma (CTCL) |
| Funding Source: | RAPT Therapeutics, Inc |
| Role: | PI |
| ID: | 00023640 |
| Date: | 2018 - 2020 |
| Title: | Biomarkers in Patients with Advanced CTCL in ONC201 Phase II Clinical Trial |
| Funding Source: | Drs Martin and Dorothy Spatz Charitable Foundation |
| Role: | PI |
| ID: | FP00005078 |
| Date: | 2018 - Present |
| Title: | Pathogenesis of Cutaneous T-cell Lymphoma and Therapeutic Development |
| Funding Source: | Sherry Anderson CTCL Research |
| Role: | PI |
| Date: | 2018 - 2021 |
| Title: | New molecular targets for cutaneous T-cell lymphoma (CTCL) |
| Funding Source: | Drs Martin and Dorothy Spatz Charitable Foundation |
| Role: | PI |
| Date: | 2015 - 2017 |
| Title: | Janus kinase 3 (JAK3) gene fusion(s) - a potential druggable target in cutaneous T-cell lymphoma |
| Funding Source: | Institutional Research Grant (IRG) Program |
| Role: | PI |
| Date: | 2012 |
| Title: | Molecular targets of CTCL |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| Date: | 2012 - 2020 |
| Title: | Effect of new Cellex Photopheresis System on the cellular immunity in CTCL patients |
| Funding Source: | Therakos, Inc |
| Role: | PI |
| Date: | 2011 - 2013 |
| Title: | Cytokine microarrays to determine new biomarkers of progressive mycosis fungoides |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| Date: | 2010 - 2015 |
| Title: | Identifying biomarkers of response and resistance to ECP in patients with MF/SS |
| Funding Source: | Therakos, Inc |
| Role: | PI |
| ID: | LS2010-00033111JW 01 |
| Date: | 2009 - 2012 |
| Title: | Effect of anti-CC chemokine receptor 4 (CCR4) monoclonal antibody on regulatory T cells and natural killer cells in patients with aggressive/refractory cutaneous T-cell lymphoma |
| Funding Source: | Kyowa Hakko Kirin Co. Ltd |
| Role: | PI |
| ID: | LS2009-00025650JW |
| Date: | 2007 - 2011 |
| Title: | Immunologic mechanisms of extracorporeal photopheresis in cutaneous T- cell lymphomas: Induction of antigen-specific cytotoxic T cells or regulatory T cells? |
| Funding Source: | Therakos, Inc |
| Role: | PI |
| ID: | LS2006-00018652AB |
| Date: | 2005 - 2007 |
| Title: | Induction of Polyclonal T-cell Responses against Cutaneous T-cell Lymphomas by Autologous Dendritic Cells Transfected with Amplified Tumor RNA |
| Funding Source: | Ladies Leukemia League |
| Role: | PI |
| ID: | 13424 |
| Date: | 2003 - 2005 |
| Title: | Strategies for effective ex vivo priming of cutaneous T-cell lymphoma -specific cytotoxic T lymphocytes by autologous dendritic cells pulsed with whole tumor cells |
| Funding Source: | Dermatology Foundation |
| Role: | PI |
| ID: | GCJ7001Z |
Selected Publications
Review Articles
- Kashyap A, Dai J, Ni X. Therapeutic Targeting of the Janus Kinase/Signal Transducer and Activator of Transcription Pathway in Cutaneous T-Cell Lymphoma. Cancers (Basel) 17(4):568, 2025. e-Pub 2025. PMID: 40002165.
- Ni X, Langridge T, Duvic M. Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab. Oncoimmunology 4(7):e1011524, 2015. e-Pub 2015. PMID: 26140234.
Abstracts
- Zhang, X, Ni, X. Effects of JAK/STAT inhibitors in cutaneous T-cell lymphoma cells. 2025 SID Annual Meeting, 2025. e-Pub 2025.
- Mayo J, Velatooru L, Wang X, Duvic M, Ni X. Effects of MALT1 inhibitors on cutaneous T-cell lymphoma cells. Journal of Investigative Dermatology 143(5):S272, 2023. e-Pub 2023.
- Ni X, Bojaxhi P, Hu CH, Bijani P, Chen H, Madeleine. Oncogenic JAK3 mRNA isoform in cutaneous T-cell lymphoma. Journal of Investigative Dermatology 141(5):S12, 2021. e-Pub 2021.
- Enriquez JS, Bijani P, Duvic M, Ni X. Effects of CCR4 antagonists in cutaneous T-cell lymphoma cells. Journal of Investigative Dermatology 140(7):S80, 2020. e-Pub 2020.
- Ni X, Hu C, Amador AD, Xue Y, Duvic M. C1014T single nucleotide polymorphism of CCR4 is frequent in Caucasian patients with cutaneous T-cell lymphoma. Journal of Investigative Dermatology 138(5, supplement):Page S27, 2018. e-Pub 2018.
- Ni, Maiti X, Langridge S, Cooper T, Duvic L, M. Monitoring malignant T-cell clones by direct TCR expression assay in patients with leukemic cutaneous T-cell lymphoma over extracorporeal photopheresis. Journal of Investigative Dermatology 137(5, Supplement 1):S113, 2017. e-Pub 2017.
- Langridge T, Austin M, Zhang X, Bojaxhi P, Shiue L, Duvic M, Ni X. Augmentation of monocyte-derived dendritic Cells by extracorporeal photopheresis in patients with leukemic cutaneous t-cell lymphoma. Journal of Investigative Dermatology 136(5):S1, 2016. e-Pub 2016.
- Ying Z, Duvic M, Shiue L, Goswami M, Langridge T, Ni X. Blood Transcriptional Profiling in Patients with Leukemic Cutaneous T-Cell Lymphoma on Extracorporeal Photopheresis Reveals the Integrin Signaling as the Top Pathway Associated with Clinical Response. Blood 126(23):#3981, 2015. e-Pub 2015.
- Ying Z, Langridge T, Shiue L, Duvic M, Ni X. Circulating cell-free DNA is increased in sera of Sezary syndrome patients. Journal of investigative dermatology 135(Supplement 2s):S17, 2015. e-Pub 2015.
- Zhang X, Ni X, Langridge T, Duvic M. ONC201 induces apoptosis, inhibits proliferation, and affects cell cycle in cutaneous T-cell lymphoma cells. Journal of investigative dermatology 135(Spplement 2s):S73, 2015. e-Pub 2015.
- Yang B, Duvic M, Shiue L, Goswami M, Langridge T, Ni X. Gene expression profiling of T-cell signaling in cutaneous T-cell lymphoma and the effect by extracorporeal photopheresis. Journal of Investigative Dermatology 134(Supplement 1s):S94, 2014. e-Pub 2014.
- Wheeler DA, Xi L, Ni X, Koshelev M, Drummond J, Muzny DM, Zhang X, Duvic M. Whole Exome Sequencing and Analysis of Mutations In Sézary Syndrome. Blood 122, 2013. e-Pub 2013.
- Ni X, Goswami M, Duvic M. Potential driver genes in the development and progression of cutaneous T-cell lymphoma. J Invest Dermatol 133(Supplement 1):S61, 2013. e-Pub 2013.
- Duvic M, Pinter-Brown L, Foss F, Sokol L, Jorgensen J, Ni X, Challagundla P, Goswami M, Dwyer K, Mohamed N, Kim AY. Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4). Blood 120(ASH Annual Meeting Abstracts), 2012. e-Pub 2012.
- Zhong H, Shiue L, Mekhail Y, Goswami M, Duvic M, Ni X. Effect of extracorporeal photopheresis on Th1/Th2/Th17/Treg cytokines in cutaneous T-cell lymphoma patients. J Invest Dermatol 132(S85-S96):S90, 2012. e-Pub 2012.
- Ni X, Jorgensen J, Goswami M, Challagundla P, Decker W, Kim Y, Duvic M. Effects of Anti-CCR4 Antibody (KW-0761) on Regulatory T Cells and Natural Killer Cells in Patients with Cutaneous T-Cell Lymphoma. Blood 118:444, 2011. e-Pub 2011.
- Shiue LH, Goswami M, Alousi A, Hosing C, Duvic M, Ni X. Effect of extracorporeal photopheresis on dendritic cell populations in patients with Sézary syndrome and graft versus host disease. Journal of Investigative Dermatology 130(S1):S119, 2010. e-Pub 2010.
- Ni X, Goswami M, Shiue LH, Dougherty A, and Duvic M. Increased Twist expression in advanced stage of CTCL. Journal of Investigative Dermatology 130(S1), 2010. e-Pub 2010.
- Shiue LH, Ahkus E, Arias-Mendoza P, Duvic M, Ni X. Increased levels of CD4+25high regulatory T cells in patients with cutaneous T-cell lymphoma after extracorporeal photopheresis. Journal of Investigative Dermatology 129(S1):S46, 2009. e-Pub 2009.
- Dougherty A, Shiue L, Bassett R, Duvic M, Prieto V, and Ni X. Increased Syndecan-4 expression in malignant T -lymphocytes is associated with progression in Mycosis Fungoides. Journal of Investigative Dermatology 129(S1):S45, 2009. e-Pub 2009.
- Ni X, Shiue L, Arias-Mendoza P, Aakhus E, Hosing C, and Duvic M. Foxp3 Expression is Induced in Peripheral Blood Mononuclear Cells from Patients with CTCL and GVHD after Extracorporeal Photopheresis. Blood 112:2912, 2008. e-Pub 2008.
- Ni X, Zhou WH, Shiue L, Aakhus E, Duvic M. A novel approach to study tumor-specific CD8+ cytotoxic T lymphocyte in cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis. J Invest Dermatol 129, 2008. e-Pub 2008.
- Ni X, Richmond H, Liao X, Shiue L, Shpall E, Duvic M. Induction of Polyclonal T-cell Responses Directed Against Cutaneous T-cell Lymphomas by Autologous Dendritic Cells Transfected with Amplified Tumor RNA. Blood 109, 2007. e-Pub 2007.
- Li B, Zhang C, Kelly C, Ni X, Duvic M. Induction of apoptosis and inhibition of STAT6 activation are associated with the clinical response to vorinostat in cutaneous T-cell lymphoma patients. J Invest Dermatol 127:S43, 2007. e-Pub 2007.
- Ni X, Richmond H, Shiue L, Shpall E, Duvic M. Ex vivo induction of polyclonal T-cell responses against cutaneous T-cell lymphoma by autologous dendritic cells transfected with amplified tumor RNA. J Invest Dermatol 127:S115, 2007. e-Pub 2007.
- Ni X, Kelly C, Talpur R, Zhang C, Breuer-Mc-Ham J, Richon V, Duvic M. Anti-angiogenic effect of vorinostat (suberoylanilide hydroxamic acid, SAHA), a histone deacetylase inhibitor, in CTCL lesions. J Invest Dermatol 126:2, 2006. e-Pub 2006.
- Doherty S, Ni X, Doherty C, Jones D, Zhao X, Owen L, Duvic M. Interleukin-23 is increased in mycosis fungoides lesions and decreased in Sezary Syndrome. J Invest Dermatol 126:115, 2006. e-Pub 2006.
- Zhang C, Sethi G, Hazarika P, Ni X, Aggarwal B, Duvic M. Curcumin induces apoptosis in cutaneous T cell lymphoma cell through targeting Stat3 and NF-kB signal pathway. J Invest Dermatol 126:37, 2006. e-Pub 2006.
- Ni X, Richmond H, Shpall E, Duvic M. Induction of Polyclonal T-Cell Responses against Cutaneous T-Cell Lymphomas by Autologous Dendritic Cells Transfected with Amplified Tumor RNA. Blood 108:5189, 2006. e-Pub 2006.
- Ni X, Liao XS, Zhang CS, Segall H, Shpall E, Duvic M. UVB induced - apoptotic Sézary cells are superior to tumor cell lysates in priming of IFN-g -secreting cytotoxic T cells in vitro. J Invest Dermatol 124:A112, 2005. e-Pub 2005.
- Zhang CL, Ni X, Talpur R, Richon V, Duvic M. Histone deacetylation and DNA methylation: novel epigenetic therapeutic target in cutaneous T cell lymphomas. J Invest Dermatol 122(3):A41, 2004. e-Pub 2004.
- Ni X, Liao XS, Segall H, Zhang CL, Shpall E, Duvic M. Apoptotic cells and tumor cell lysate pulsed CD14+monocyte-derived dendritic cells from cutaneous T-cell lymphoma mature and induce allogenic T-cell proliferation in vitro. J Invest Dermatol 122(3):A121, 2004. e-Pub 2004.
- Ni X, Talpur R, Herne K, Schulz C, Sui D, Ward S, Hazarika P, Josephs A, Duvic M. Tazarotene induced gene-3 is suppressed in basal cell carcinomas and upregulated by tazarotene in vivo. J Invest Dermatol 121(1):191, 2003. e-Pub 2003.
- Zhang CL, Ni X, Talpur R, Richon V, Duvic M. A histone deacetylase inhibitor induces apoptosis in cutaneous T cell lymphoma cells and is synergistic with 5-aza-2-deoxycytidine. Blood 102(11):2403, 2003. e-Pub 2003.
- Zhang CL, Ni X, Konopleva M, Milella M, Hazarika P, Andreef M, Duvic M. Peroxisome proliferator activator receptor-g and retinoid X receptor agonists exert synergistic proapoptotic effects on cutaneous T-cell lymphoma cells. J Invest Dermatol 119(1):345, 2002. e-Pub 2002.
- Hazarika P, Geoge S, Prieto V, Ni X, Bar-Eli MM, Duvic M. Over-expression of a novel caveolae associated protein, Flotillin-2, is associated with melanoma progression. J Invest Dermatol 119(1):223, 2002. e-Pub 2002.
- Ni X, Zhang CL, Hazarika P, Duvic M. Functional Fas ligand is expressed in human cutaneous T cell lymphoma cells and inhibited by Bexarotene. J Invest Dermatol 119(1):217, 2002. e-Pub 2002.
- Ni X, Zhang CL, Hazarika P, Duvic M. Fas/Fas ligand-mediated elimination of cytotoxic CD8+ lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?. J Invest Dermatol 117(2):490, 2001. e-Pub 2001.
Book Chapters
- Ni X. Dermatopathology - Introduction. In: The Basis of Modern Dermatology. The People's Medical Publishing House, 1035-1063, 2001.
- Ni X, Sun J, Liu J. Dermatopathology in China. In: Chinese Modern Scientific Encyclopedia. Scientific Publishing House, 2000.
- Ni X. Benign and Malignant epidermal tumors. In: Atlas of Dermatology and Venereology. The People's Medical Publishing House, 337-354, 1998.
Patient Reviews
CV information above last modified July 22, 2026